PriceTargets.com logo

Elevance Health - ELV Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $398.44
  • Forecasted Upside: 19.45%
  • Number of Analysts: 23
  • Breakdown:
  • 0 Sell Ratings
  • 11 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$333.57 As of 12/4/2025 04:59 PM ET
▲ +2.818 (0.85%)

This chart shows the closing price for ELV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Elevance Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELV

Analyst Price Target is $398.44
▲ +19.45% Upside Potential
This price target is based on 23 analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $398.44, with a high forecast of $485.00 and a low forecast of $297.00. The average price target represents a 19.45% upside from the last price of $333.57.

This chart shows the closing price for ELV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 23 contributing investment analysts is to moderate buy stock in Elevance Health. This rating has held steady since October 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 1 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 12 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 12 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 11 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsUpgradeSell (D+) ➝ Hold (C-)
11/26/2025CowenReiterated RatingBuy ➝ Buy
11/26/2025TD CowenBoost TargetBuy ➝ Buy$380.00 ➝ $400.00
11/24/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/17/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/11/2025Weiss RatingsDowngradeHold (C-) ➝ Sell (D+)
11/6/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
11/3/2025MizuhoLower TargetOutperform ➝ Outperform$420.00 ➝ $400.00
10/28/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$384.00 ➝ $394.00
10/23/2025CowenReiterated RatingBuy ➝ Buy
10/23/2025TD CowenBoost TargetBuy ➝ Buy$330.00 ➝ $380.00
10/22/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$412.00 ➝ $403.00
10/22/2025BarclaysLower TargetOverweight ➝ Overweight$395.00 ➝ $385.00
10/16/2025Sanford C. BernsteinLower TargetOutperform ➝ Outperform$445.00 ➝ $420.00
10/14/2025Truist FinancialSet Target$400.00
10/14/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$316.00 ➝ $359.00
10/14/2025The Goldman Sachs GroupInitiated CoverageNeutral$343.00
10/14/2025The Goldman Sachs GroupInitiated CoverageNeutral$343.00
10/10/2025Bank of AmericaBoost TargetNeutral ➝ Neutral$330.00 ➝ $370.00
10/9/2025MizuhoBoost TargetOutperform ➝ Outperform$342.00 ➝ $420.00
10/9/2025BarclaysBoost TargetOverweight ➝ Overweight$373.00 ➝ $395.00
10/8/2025GuggenheimBoost TargetBuy ➝ Buy$360.00 ➝ $398.00
10/8/2025Weiss RatingsUpgradeSell (D+) ➝ Hold (C-)
10/7/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$330.00 ➝ $412.00
9/27/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
9/5/2025UBS GroupLower TargetBuy ➝ Buy$435.00 ➝ $425.00
9/4/2025BarclaysBoost TargetOverweight ➝ Overweight$327.00 ➝ $373.00
8/15/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$400.00 ➝ $330.00
7/25/2025Robert W. BairdLower TargetNeutral ➝ Neutral$492.00 ➝ $297.00
7/22/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$472.00 ➝ $384.00
7/21/2025ArgusReiterated RatingBuy ➝ Hold
7/18/2025BarclaysLower TargetOverweight ➝ Overweight$434.00 ➝ $358.00
7/18/2025GuggenheimLower TargetBuy ➝ Buy$447.00 ➝ $360.00
7/18/2025Leerink PartnersReiterated RatingOutperform ➝ Market Perform$510.00 ➝ $310.00
7/18/2025Morgan StanleyLower TargetOverweight ➝ Overweight$428.00 ➝ $316.00
7/17/2025Leerink PartnrsDowngradeStrong-Buy ➝ Hold
7/16/2025Truist FinancialLower TargetBuy ➝ Buy$500.00 ➝ $440.00
7/15/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$478.00 ➝ $400.00
7/14/2025UBS GroupReiterated RatingBuy ➝ Buy$555.00 ➝ $484.00
7/9/2025BarclaysLower TargetOverweight ➝ Overweight$480.00 ➝ $434.00
6/9/2025Truist FinancialSet TargetBuy ➝ Buy$510.00 ➝ $500.00
6/4/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$478.00
6/2/2025BarclaysLower TargetOverweight ➝ Overweight$522.00 ➝ $480.00
4/25/2025ArgusSet Target$465.00
4/23/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$478.00 ➝ $478.00
4/23/2025GuggenheimReiterated RatingBuy ➝ Buy$518.00 ➝ $518.00
4/23/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$485.00 ➝ $485.00
4/23/2025BarclaysBoost TargetOverweight ➝ Overweight$512.00 ➝ $522.00
4/15/2025Baird R WDowngradeStrong-Buy ➝ Hold
4/15/2025Robert W. BairdReiterated RatingOutperform ➝ Neutral$625.00 ➝ $529.00
4/11/2025Truist FinancialBoost TargetBuy ➝ Buy$480.00 ➝ $510.00
4/9/2025GuggenheimInitiated CoverageBuy$518.00
4/9/2025MizuhoBoost TargetOutperform ➝ Outperform$455.00 ➝ $505.00
3/28/2025Sanford C. BernsteinReiterated RatingOutperform ➝ Outperform
3/17/2025ArgusUpgradeHold ➝ Buy$450.00
1/29/2025ArgusReiterated RatingHold ➝ Hold$405.40 ➝ $405.40
1/28/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$483.00 ➝ $478.00
1/24/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$485.00 ➝ $485.00
1/24/2025BarclaysBoost TargetOverweight ➝ Overweight$501.00 ➝ $512.00
1/22/2025StephensDowngradeOverweight ➝ Equal Weight$520.00 ➝ $440.00
1/6/2025Truist FinancialLower TargetBuy ➝ Buy$520.00 ➝ $480.00
11/5/2024MizuhoLower TargetOutperform ➝ Outperform$585.00 ➝ $505.00
11/4/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$593.00 ➝ $495.00
10/23/2024Morgan StanleyLower TargetOverweight ➝ Overweight$643.00 ➝ $551.00
10/22/2024BarclaysLower TargetOverweight ➝ Overweight$622.00 ➝ $501.00
10/21/2024TD CowenLower TargetBuy ➝ Buy$589.00 ➝ $484.00
10/18/2024Raymond James FinancialSet Target$485.00
10/18/2024Wells Fargo & CompanyReiterated RatingBuy ➝ Buy
10/18/2024StephensReiterated RatingUnderperform ➝ Underperform
10/18/2024UBS GroupLower TargetBuy ➝ Buy$605.00 ➝ $555.00
10/18/2024Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$585.00 ➝ $478.00
10/18/2024Truist FinancialReiterated RatingBuy ➝ Buy$620.00 ➝ $520.00
10/18/2024Cantor FitzgeraldLower TargetOverweight ➝ Overweight$600.00 ➝ $485.00
10/18/2024ArgusDowngradeBuy ➝ Hold
10/10/2024BarclaysBoost TargetOverweight ➝ Overweight$611.00 ➝ $622.00
10/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$600.00 ➝ $600.00
9/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$600.00 ➝ $600.00
9/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$600.00 ➝ $600.00
9/5/2024StephensReiterated RatingOverweight ➝ Overweight$615.00 ➝ $615.00
8/19/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$600.00 ➝ $600.00
7/23/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$600.00 ➝ $600.00
7/22/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$600.00 ➝ $593.00
7/19/2024TD CowenLower TargetBuy ➝ Buy$624.00 ➝ $589.00
7/18/2024BarclaysLower TargetOverweight ➝ Overweight$621.00 ➝ $611.00
7/18/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$575.00 ➝ $585.00
7/18/2024Bank of AmericaReiterated RatingBuy ➝ Neutral$646.00 ➝ $530.00
7/15/2024Truist FinancialBoost TargetBuy ➝ Buy$600.00 ➝ $620.00
7/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$600.00 ➝ $600.00
6/24/2024Morgan StanleyInitiated CoverageOverweight$643.00
6/12/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$600.00 ➝ $600.00
6/11/2024StephensReiterated RatingOverweight ➝ Overweight$615.00 ➝ $615.00
6/4/2024Bank of AmericaBoost TargetBuy ➝ Buy$621.00 ➝ $646.00
5/30/2024Baird R WUpgradeStrong-Buy
5/30/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$628.00 ➝ $631.00
5/30/2024Robert W. BairdInitiated CoverageOutperform$649.00
4/24/2024MizuhoBoost TargetBuy ➝ Buy$575.00 ➝ $585.00
4/19/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$574.00 ➝ $575.00
4/19/2024UBS GroupBoost TargetBuy ➝ Buy$585.00 ➝ $605.00
4/19/2024Truist FinancialReiterated RatingBuy ➝ Buy$580.00 ➝ $600.00
4/19/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$557.00 ➝ $600.00
4/19/2024BarclaysBoost TargetOverweight ➝ Overweight$584.00 ➝ $621.00
4/19/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$602.00 ➝ $604.00
4/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$580.00
4/8/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$561.00 ➝ $557.00
4/4/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$580.00
3/6/2024BarclaysInitiated CoverageOverweight$584.00
2/14/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$547.00 ➝ $580.00
2/2/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$547.00
1/25/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$547.00
1/25/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$572.00 ➝ $574.00
1/19/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$547.00
11/21/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$547.00
11/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$569.00 ➝ $552.00
10/19/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$547.00
10/19/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$585.00 ➝ $587.00
9/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$547.00
7/25/2023Morgan StanleyBoost TargetOverweight$571.00 ➝ $585.00
7/24/2023TD CowenBoost TargetOutperform$564.00 ➝ $585.00
7/20/2023Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$572.00
7/20/2023StephensReiterated RatingOverweight ➝ Overweight$555.00
7/12/2023Wolfe ResearchDowngradeOutperform ➝ Peer Perform
7/7/2023JPMorgan Chase & Co.Lower Target$572.00 ➝ $535.00
6/20/2023Truist FinancialLower Target$580.00 ➝ $560.00
4/27/202322nd Century GroupReiterated RatingUpgrade
4/27/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$500.00 ➝ $571.00
4/24/2023Wells Fargo & CompanyLower Target$597.00 ➝ $561.00
4/21/2023Loop CapitalLower TargetBuy$565.00 ➝ $550.00
4/20/2023Cantor FitzgeraldInitiated CoverageOverweight$547.00
4/20/2023Deutsche Bank AktiengesellschaftBoost Target$571.00 ➝ $575.00
4/20/2023TD CowenLower TargetOutperform$577.00 ➝ $564.00
3/28/2023Royal Bank Of CanadaUpgradeSector Perform ➝ Outperform$523.00 ➝ $572.00
3/24/2023Truist FinancialLower TargetBuy$610.00 ➝ $580.00
3/21/2023Wells Fargo & CompanyLower TargetEqual Weight$609.00 ➝ $597.00
3/8/2023Deutsche Bank AktiengesellschaftLower TargetBuy$581.00 ➝ $571.00
2/23/2023JPMorgan Chase & Co.Boost TargetOverweight$555.00 ➝ $572.00
1/30/2023Loop CapitalBoost Target$550.00 ➝ $565.00
1/26/2023Royal Bank Of CanadaBoost TargetSector Perform$505.00 ➝ $523.00
1/26/2023Leerink PartnersReiterated RatingOutperform$580.00
1/4/2023Wells Fargo & CompanyBoost TargetOverweight$557.00 ➝ $609.00
11/10/2022MizuhoBoost TargetBuy$545.00 ➝ $575.00
10/24/2022UBS GroupBoost Target$585.00 ➝ $610.00
10/21/2022Morgan StanleyBoost TargetEqual Weight$485.00 ➝ $500.00
10/21/2022Deutsche Bank AktiengesellschaftBoost TargetBuy$576.00 ➝ $581.00
9/9/2022Bank of AmericaUpgradeNeutral ➝ Buy$535.00 ➝ $575.00
8/22/2022Leerink PartnersUpgradeMarket Perform ➝ Outperform$490.00 ➝ $580.00
7/25/2022Morgan StanleyLower TargetEqual Weight$533.00 ➝ $485.00
7/22/2022StephensLower Target$550.00
7/22/2022CowenLower Target$577.00
7/22/2022Leerink PartnersLower TargetMarket Perform ➝ Market Perform$555.00 ➝ $490.00
7/21/2022Royal Bank Of CanadaLower Target$544.00 ➝ $505.00
6/22/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$607.00 ➝ $533.00
6/16/2022Loop CapitalInitiated CoverageBuy$550.00
5/26/2022Sanford C. BernsteinInitiated CoverageOutperform$577.00 ➝ $596.00
5/25/2022Wells Fargo & CompanyLower TargetOverweight$586.00 ➝ $580.00
5/4/2022MizuhoBoost Target$510.00 ➝ $545.00
4/25/2022BMO Capital MarketsBoost TargetOutperform$540.00 ➝ $625.00
4/22/2022Wells Fargo & CompanySet TargetOverweight$460.00 ➝ $586.00
4/22/2022Deutsche Bank AktiengesellschaftBoost TargetBuy$453.00 ➝ $574.00
4/21/2022CowenBoost Target$472.00 ➝ $642.00
4/21/2022Jefferies Financial GroupBoost Target$575.00 ➝ $625.00
4/21/2022Truist FinancialBoost Target$590.00 ➝ $610.00
4/21/2022CowenBoost Target$472.00 ➝ $642.00
4/21/2022Morgan StanleyBoost TargetOverweight$518.00 ➝ $607.00
4/21/2022Leerink PartnersBoost TargetMarket Perform$483.00 ➝ $555.00
4/21/2022The Goldman Sachs GroupBoost TargetBuy$527.00 ➝ $605.00
4/21/2022Credit Suisse GroupBoost TargetOutperform$518.00 ➝ $584.00
4/7/2022Truist FinancialBoost Target$540.00 ➝ $590.00
3/29/2022Jefferies Financial GroupReiterated RatingBuy ➝ Buy$559.00
3/29/2022UBS GroupBoost TargetBuy$477.00 ➝ $541.00
3/15/2022Leerink PartnersBoost TargetMarket Perform$465.00 ➝ $483.00
2/7/2022ArgusBoost TargetBuy$475.00 ➝ $500.00
1/28/2022Morgan StanleyLower TargetOverweight$561.00 ➝ $518.00
1/27/2022Leerink PartnersBoost TargetMarket Perform$430.00 ➝ $465.00
1/11/2022Sanford C. BernsteinBoost Target$559.00 ➝ $574.00
1/5/2022Truist FinancialBoost TargetBuy ➝ Buy$490.00 ➝ $540.00
12/20/2021MizuhoUpgradeNeutral ➝ Buy$450.00 ➝ $510.00
12/17/2021Morgan StanleyBoost TargetOverweight$486.00 ➝ $561.00
12/14/2021The Goldman Sachs GroupInitiated CoverageConviction-Buy$517.00
10/29/2021MizuhoBoost TargetNeutral$385.00 ➝ $450.00
10/25/2021ArgusBoost TargetBuy$435.00 ➝ $475.00
10/25/2021Wells Fargo & CompanyBoost TargetOverweight$460.00 ➝ $500.00
10/22/2021BMO Capital MarketsBoost TargetOutperform$465.00 ➝ $500.00
10/22/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$408.00 ➝ $460.00
10/21/2021Truist FinancialBoost TargetBuy$450.00 ➝ $490.00
10/21/2021Morgan StanleyBoost TargetOverweight$468.00 ➝ $486.00
10/21/2021Leerink PartnersBoost TargetMarket Perform$403.00 ➝ $430.00
10/21/2021Credit Suisse GroupBoost TargetOutperform$425.00 ➝ $486.00
10/21/2021Royal Bank Of CanadaBoost TargetSector Perform$408.00 ➝ $452.00
10/21/2021StephensBoost TargetOverweight$440.00 ➝ $475.00
10/21/2021BarclaysBoost TargetOverweight$450.00 ➝ $485.00
10/21/2021CitigroupBoost TargetBuy$445.00 ➝ $497.00
9/27/2021Leerink PartnersInitiated CoverageMarket Perform$403.00
9/9/2021CowenInitiated CoverageOutperform$465.00
8/31/2021Morgan StanleyBoost TargetOverweight$459.00 ➝ $468.00
7/22/2021Jefferies Financial GroupBoost TargetBuy$447.00 ➝ $453.00
7/22/2021StephensBoost TargetOverweight$430.00 ➝ $440.00
7/22/2021BMO Capital MarketsBoost TargetOutperform$450.00 ➝ $465.00
7/22/2021BarclaysBoost TargetOverweight$425.00 ➝ $450.00
7/22/2021Cantor FitzgeraldBoost TargetOverweight$430.00 ➝ $455.00
7/22/2021MizuhoBoost TargetNeutral$380.00 ➝ $385.00
7/22/2021Royal Bank Of CanadaBoost TargetSector Perform$399.00 ➝ $408.00
7/9/2021Seaport Res PtnReiterated RatingBuy
7/2/2021Morgan StanleyBoost TargetOverweight$454.00 ➝ $459.00
6/10/2021Royal Bank Of CanadaDowngradeOutperform ➝ Sector Perform$399.00
5/24/2021Wells Fargo & CompanyInitiated CoverageOverweight$460.00
5/18/2021Wells Fargo & CompanyInitiated CoverageOverweight$460.00
5/6/2021ArgusBoost TargetAverage ➝ Buy$330.00 ➝ $435.00
5/3/2021MizuhoBoost TargetNeutral$320.00 ➝ $380.00
4/22/2021Truist FinancialBoost Target$425.00 ➝ $450.00
4/22/2021StephensBoost TargetOverweight$395.00 ➝ $430.00
4/22/2021BMO Capital MarketsBoost TargetOutperform$440.00 ➝ $450.00
4/22/2021Royal Bank Of CanadaBoost TargetOutperform$350.00 ➝ $399.00
4/22/2021BarclaysBoost TargetOverweight$375.00 ➝ $425.00
4/20/2021Truist FinancialBoost TargetBuy$425.00 ➝ $450.00
4/14/2021Truist FinancialBoost Target$375.00 ➝ $425.00
4/14/2021CowenBoost TargetOutperform$360.00 ➝ $395.00
3/9/2021Truist FinancialUpgradeHold ➝ Buy$360.00 ➝ $375.00
3/4/2021Truist FinancialUpgradeHold ➝ Buy$360.00 ➝ $375.00
1/28/2021Credit Suisse GroupLower TargetOutperform$389.00 ➝ $382.00
1/28/2021StephensLower TargetOverweight$350.00 ➝ $340.00
1/26/2021CowenBoost TargetOutperform$330.00 ➝ $360.00
1/15/2021Jefferies Financial GroupUpgradeHold ➝ Buy$305.00 ➝ $402.00
1/13/2021ArgusBoost TargetOutperform ➝ Buy$300.00 ➝ $380.00
1/5/2021Truist FinancialBoost Target$320.00 ➝ $360.00
12/18/2020MizuhoBoost TargetNeutral$300.00 ➝ $320.00
12/14/2020Leerink PartnersBoost TargetOutperform$370.00 ➝ $400.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.48 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 10 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 108 very positive mentions
  • 19 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
10/5/2025
  • 111 very positive mentions
  • 44 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 146 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 146 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Elevance Health logo
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $333.57
Low: $328.31
High: $336.45

50 Day Range

MA: $333.98
Low: $303.18
High: $362.47

52 Week Range

Now: $333.57
Low: $273.71
High: $458.75

Volume

2,357,293 shs

Average Volume

1,435,720 shs

Market Capitalization

$74.13 billion

P/E Ratio

13.64

Dividend Yield

2.07%

Beta

0.52

Frequently Asked Questions

What sell-side analysts currently cover shares of Elevance Health?

The following Wall Street sell-side analysts have issued reports on Elevance Health in the last year: Argus, Baird R W, Bank of America Corporation, Barclays PLC, Cantor Fitzgerald, Cowen Inc, Guggenheim, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Mizuho, Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, Sanford C. Bernstein, Stephens, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Corporation, UBS Group AG, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for ELV.

What is the current price target for Elevance Health?

0 Wall Street analysts have set twelve-month price targets for Elevance Health in the last year. Their average twelve-month price target is $398.44, suggesting a possible upside of 19.4%. Cantor Fitzgerald has the highest price target set, predicting ELV will reach $485.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $297.00 for Elevance Health in the next year.
View the latest price targets for ELV.

What is the current consensus analyst rating for Elevance Health?

Elevance Health currently has 11 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ELV.

What other companies compete with Elevance Health?

Other companies that are similar to Elevance Health include Centene, Molina Healthcare, UnitedHealth Group, Cigna Group and Humana. Learn More about companies similar to Elevance Health.

How do I contact Elevance Health's investor relations team?

Elevance Health's physical mailing address is 220 VIRGINIA AVENUE, INDIANAPOLIS IN, 46204. The company's listed phone number is (800) 331-1476 and its investor relations email address is [email protected]. The official website for Elevance Health is www.antheminc.com. Learn More about contacing Elevance Health investor relations.